-
Dec. 01, 2023SanegeneBio Raised nearly $100 Million in Series A+ Financing Led by Tencent Investment and Yuanbio Venture Capital, to Advance Development of RNAi TherapeuticsMore
-
Nov. 09, 2023SanegeneBio and Huadong Medicine Collaborate to Develop Novel siRNA Drugs for the Treatment of Chronic Metabolic DiseasesMore
-
Oct. 07, 2023SanegeneBio first RNAi drug was approved for clinical trial in ChinaMore
-
Jul. 12, 2023Pharma DJ: SanegeneBio: an innovator for RNAi drugsPharmaDJ interviewed SanegeneBio's CEOMore
-
May 31, 2023Sanegene Announces Dosing of the First Subject in Phase I Trial of SGB-3403 Targeting PCSK9 for the Treatment of HypercholesterolemiaMore
-
Jan. 06, 2023SanegeneBio and Orbit Discovery Collaborate to Identify Targeting Peptides for RNAi DrugsMore
